Market closed
ChromaDex/CDXC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ChromaDex
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
Ticker
CDXC
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
106
Website
ChromaDex Metrics
BasicAdvanced
$264M
Market cap
-
P/E ratio
-$0.03
EPS
1.87
Beta
-
Dividend rate
Price and volume
Market cap
$264M
Beta
1.87
52-week high
$4.65
52-week low
$1.28
Average daily volume
268K
Financial strength
Current ratio
2.759
Quick ratio
2.04
Long term debt to equity
6.963
Total debt to equity
10.17
Management effectiveness
Return on assets (TTM)
-2.68%
Return on equity (TTM)
-4.67%
Valuation
Price to revenue (TTM)
3.051
Price to book
8.54
Price to tangible book (TTM)
8.67
Price to free cash flow (TTM)
267.52
Growth
Revenue change (TTM)
5.74%
Earnings per share change (TTM)
-66.26%
3-year revenue growth (CAGR)
11.34%
3-year earnings per share growth (CAGR)
-56.63%
What the Analysts think about ChromaDex
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ChromaDex stock.
ChromaDex Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ChromaDex Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ChromaDex News
AllArticlesVideos
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
Business Wire·2 days ago
ChromaDex to Participate in the 17th Annual LD Micro Main Event
Business Wire·3 days ago
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ChromaDex stock?
ChromaDex (CDXC) has a market cap of $264M as of October 26, 2024.
What is the P/E ratio for ChromaDex stock?
The price to earnings (P/E) ratio for ChromaDex (CDXC) stock is 0 as of October 26, 2024.
Does ChromaDex stock pay dividends?
No, ChromaDex (CDXC) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next ChromaDex dividend payment date?
ChromaDex (CDXC) stock does not pay dividends to its shareholders.
What is the beta indicator for ChromaDex?
ChromaDex (CDXC) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.